<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04742218</url>
  </required_header>
  <id_info>
    <org_study_id>K-877-110</org_study_id>
    <nct_id>NCT04742218</nct_id>
  </id_info>
  <brief_title>Study to Assess the Food Effect of K-877 in Healthy Adult Volunteers</brief_title>
  <official_title>A Randomized, Open Label, Two-sequence, Two-period Crossover Study to Assess the Food Effect on the Pharmacokinetics of Single-Dose Administration of the To-Be-Marketed Formulation of K-877 in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kowa Research Institute, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kowa Research Institute, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study is to assess the effects of food on the Pharmacokinetics(PK) of single-dose&#xD;
      administration of K-877 in healthy adult volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 13, 2021</start_date>
  <completion_date type="Actual">April 11, 2021</completion_date>
  <primary_completion_date type="Actual">April 11, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of K-877</measure>
    <time_frame>pre-dose (within 1 hour before dosing and at pre-meal in case of fed condition) and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hours after dosing on Days 1 and 4</time_frame>
    <description>Observed maximum plasma concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t of K-877</measure>
    <time_frame>pre-dose (within 1 hour before dosing and at pre-meal in case of fed condition) and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hours after dosing on Days 1 and 4</time_frame>
    <description>Area under the plasma concentration versus time curve from time 0 to the time of the last quantifiable concentration (AUC0-t)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf of K-877</measure>
    <time_frame>pre-dose (within 1 hour before dosing and at pre-meal in case of fed condition) and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hours after dosing on Days 1 and 4</time_frame>
    <description>Area under the plasma concentration versus time curve from time 0 extrapolated to infinity (AUC0-inf)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax of K-877</measure>
    <time_frame>pre-dose (within 1 hour before dosing and at pre-meal in case of fed condition) and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hours after dosing on Days 1 and 4</time_frame>
    <description>Time to reach the observed maximum (peak) plasma concentration (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRT0-t of K-877</measure>
    <time_frame>pre-dose (within 1 hour before dosing and at pre-meal in case of fed condition) and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hours after dosing on Days 1 and 4</time_frame>
    <description>Mean residence time from time 0 to the time of the last quantifiable concentration (MRT0-t)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRT0-inf of K-877</measure>
    <time_frame>pre-dose (within 1 hour before dosing and at pre-meal in case of fed condition) and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hours after dosing on Days 1 and 4</time_frame>
    <description>Mean residence time from time 0 extrapolated to infinity (MRT0-inf)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of K-877</measure>
    <time_frame>pre-dose (within 1 hour before dosing and at pre-meal in case of fed condition) and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hours after dosing on Days 1 and 4</time_frame>
    <description>Terminal elimination half-life (t1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kel of K-877</measure>
    <time_frame>pre-dose (within 1 hour before dosing and at pre-meal in case of fed condition) and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hours after dosing on Days 1 and 4</time_frame>
    <description>Terminal elimination rate constant (Kel)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of K-877</measure>
    <time_frame>pre-dose (within 1 hour before dosing and at pre-meal in case of fed condition) and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hours after dosing on Days 1 and 4</time_frame>
    <description>Apparent oral clearance (CL/F)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F of K-877</measure>
    <time_frame>pre-dose (within 1 hour before dosing and at pre-meal in case of fed condition) and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hours after dosing on Days 1 and 4</time_frame>
    <description>Apparent volume of distribution (Vd/F)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>Baseline to Day 6</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Fasted-Fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of K-877 administered in a fasted condition on Day 1 (Treatment Period 1) and postprandially on Day 4 (Treatment Period 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fed-Fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of K-877 administered postprandially on Day 1 (Treatment Period 1) and in a fasted condition on Day 4 (Treatment Period 2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>K-877</intervention_name>
    <description>K-877 Tablet</description>
    <arm_group_label>Fasted-Fed</arm_group_label>
    <arm_group_label>Fed-Fasted</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject provides written informed consent before any study-specific evaluation is&#xD;
             performed;&#xD;
&#xD;
          -  Subject is a healthy adult male or female volunteer between the ages of 18 and 45&#xD;
             years, inclusive, at screening;&#xD;
&#xD;
          -  Subject has a BMI of 18 to 30 kg/m2, inclusive, at screening&#xD;
&#xD;
          -  Subject meets all inclusion criteria outlined in the clinical study protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject is a woman who is pregnant or breastfeeding;&#xD;
&#xD;
          -  Subject has clinically significant abnormalities in the screening or check-in&#xD;
             assessments;&#xD;
&#xD;
          -  Subject has received an investigational drug within 30 days or 5 half-lives (whichever&#xD;
             is longer) before the first dose of study drug&#xD;
&#xD;
          -  Subject does not meet any other exclusion criteria outlined in clinical study&#xD;
             protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shona Pendse, MD, MMSc</last_name>
    <role>Study Chair</role>
    <affiliation>Kowa Research Institute, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PPD Development, LP</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 29, 2021</study_first_submitted>
  <study_first_submitted_qc>February 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 8, 2021</study_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

